Get 40% Off
💰 Ray Dalio just increased his holdings in Google by 162.61% - See the full portfolio with InvestingPro’s free Stock Ideas toolCopy Portfolios

Nu Skin (NUS) Posts In-Line Q2 Earnings; Ups Sales View

Published 08/07/2016, 09:24 PM
Updated 07/09/2023, 06:31 AM
SJM
-
HELE
-
IPAR
-
NUS
-

Shares of Nu Skin Enterprises Inc. (NYSE:NUS) were up 11% on Aug 5 following the company's second-quarter results. While the company’s earnings matched estimates, revenues beat expectations. Further, this skin care and nutritional products retailer raised its outlook for 2016 owing to new product launches and a favorable view on currency.

Second Quarter Results in Detail

Nu Skin reported adjusted earnings of 79 cents per share in the second quarter of 2016, which increased 5.3% from 75 cents per share in the year-ago quarter. This was due to higher year-over-year revenues and improved operating margins, which offset the currency impact of 36 cents. Earnings were in line with the Zacks Consensus Estimate and also at the higher end of the company’s expectation of 75-79 cents per share attributable to better-than-expected revenues.

Despite currency headwinds, revenues of $600.5 million in the second quarter of 2016 grew 7% from the year-ago quarter, driven by significant product introduction events in South Asia/Pacific and Greater China. The company also witnessed an increase in sales leaders during the quarter, reflecting the impact of product launches.

In April, the company introduced its ageLOC Youth nutritional product in South Asia Pacific, which drove the region’s revenue growth by 42%, on a constant currency basis.

NU SKIN ENTERP Price and Consensus

NU SKIN ENTERP Price and Consensus | NU SKIN ENTERP Quote

Revenue and Margins

Revenues, excluding currency impact, increased 10% in the second quarter. The company’s performance improved significantly in EMEA, Greater China, and South Asia/Pacific, offsetting the decline in Americas and North-Asia regions, on a constant currency basis.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Revenues were higher than the company’s guided range of $560-$580 million and also beat the Zacks Consensus Estimate of $583 million by 3%.

The company's gross margin declined 160 basis points (bps) to 78.7% in the second quarter due to currency headwinds. Operating margin, on the other hand, improved 50 bps to 13.3% in the second quarter of 2016, owing to lower general and administrative expense ratio in the quarter.

Other Financial Details

During the quarter, the company paid $19.9 million of dividends and repurchased $4.3 million worth shares in the quarter, leaving the authorization at $422.7 million at the end of the quarter.

The company plans to repurchase $210 million of stock during the balance of the year.

Third Quarter Guidance

For the third quarter, revenues are expected in a range of $560 million to $580 million, assuming a negative foreign currency impact of approximately 1-2%. Earnings are expected in the range of 80 – 84 cents per share in the third quarter. The Zacks Consensus Estimate of 83 cents per share is within the guided range.

In the second half of the year, the company intends to focus on the full-time launch of ageLOC Me and its global product initiatives.

Full-Year Guidance Raised

For 2016, the company has raised its revenue guidance owing to better-than-expected second-quarter results and expectation of favorable currency impact. The company now expects revenues in a range of $2.20 to $2.24 billion, including a negative foreign currency impact of 2% to 3%. The company had previously forecast revenues in a range of $2.16 to $2.20 billion, with currency impact of 4% to 5%. Adjusted earnings are forecast in a range of $2.80 to $2.90 per share. The Zacks Consensus Estimate of $2.85 per share is within the guided range.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Nu Skin currently sports a Zacks Rank #1 (Strong Buy).

Other Stocks to Consider

Some other companies worth considering in the same space include Inter Parfums, Inc. (NASDAQ:IPAR) and Hele of Troy Ltd. (NASDAQ:HELE) . Another company which is well positioned in the broader consumer staples sector is The J. M. Smucker Co. (NYSE:SJM) . While Inter PArfums and Smucker hold the same Zacks Rank as Nu Skin, Hele of Troy carries a Zacks Rank #2 (Buy).



INTER PARFUMS (IPAR): Free Stock Analysis Report

NU SKIN ENTERP (NUS): Free Stock Analysis Report

HELEN OF TROY (HELE): Free Stock Analysis Report

SMUCKER JM (SJM): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.